Marco Sebastiani
Overview
Explore the profile of Marco Sebastiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
1920
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopalco G, Morrone M, Atzeni F, Bazzani C, Bianchi F, Cantatore F, et al.
Ther Adv Musculoskelet Dis
. 2025 Feb;
17:1759720X251315138.
PMID: 39897378
Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU's usefulness in...
2.
Ciurea A, Kissling S, Gotschi A, Ornbjerg L, Rasmussen S, Tamasi B, et al.
Arthritis Res Ther
. 2025 Jan;
27(1):18.
PMID: 39891200
Background: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated...
3.
Pappa M, Koutsogianni A, Karamanakos A, Kyriazi N, Cheila M, Moschou D, et al.
Rheumatol Int
. 2025 Jan;
45(1):15.
PMID: 39751658
Introduction: Hepatitis B reactivation and administration of prophylactic antiviral treatment are considered in patients with autoimmune inflammatory rheumatic diseases (AIIRD) undergoing immunosuppressive/immunomodulatory treatment. Data are more robust for rheumatoid arthritis...
4.
Sebastiani M, Lepri G, Iannone C, Bozzalla Cassione E, Guggino G, Lo Monaco A, et al.
J Rheumatol
. 2024 Dec;
PMID: 39681380
Objective: Some concerns remain about the safety of nintedanib in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD), such as in the presence of comorbidities or in combination with biologic,...
5.
Lubrano E, Lubrano E, Armuzzi A, Armuzzi A, Scriffignano S, Scriffignano S, et al.
Reumatismo
. 2024 Nov;
PMID: 39526478
Objective: To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD). Methods: An exhaustive literature search was...
6.
Manfredi A, Venerito V, Cazzato M, Sambataro G, Zanini U, Gozzi F, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518649
Progressive pulmonary fibrosis (PPF) has been associated with a worse prognosis, even when interstitial lung disease (ILD) is related to rheumatic diseases. Since many differences are detectable among rheumatic diseases...
7.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, et al.
Arthritis Rheumatol
. 2024 Oct;
PMID: 39467037
Objective: Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical and serological features associated with...
8.
Luppi F, Manfredi A, Faverio P, Franco G, Salvarani C, Bendstrup E, et al.
Autoimmun Rev
. 2024 Oct;
23(12):103668.
PMID: 39413945
Interstitial lung disease (ILD) is a relevant cause of morbidity and mortality in patients with autoimmune rheumatic diseases (ARDs). In the last years, an acute exacerbation (AE) - defined as...
9.
Luppi F, Sebastiani M
Nat Rev Rheumatol
. 2024 Sep;
20(11):669-670.
PMID: 39232244
No abstract available.
10.
Manfredi A, Sambataro G, Rai A, Cerri S, Sambataro D, Vacchi C, et al.
J Pers Med
. 2024 Jul;
14(7).
PMID: 39063962
Background: Interstitial lung disease (ILD) represents a frequent cause of morbidity and mortality in primary Sjogren syndrome (pSS). However, the prevalence and behavior of pSS-ILD remains incomplete, largely based on...